Page 3 - Netherlands Cancer Institute

Oncology & Cancer

Popular immunotherapy target turns out to have a surprising buddy

The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

page 3 from 3